CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
By Dr. Matthew Watson
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS:CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range.
More here:
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
By Dr. Matthew Watson
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
By Dr. Matthew Watson
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024.
Continued here:
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
By Dr. Matthew Watson
YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.
Read the rest here:
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
By Dr. Matthew Watson
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment
Read more here:
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
By Dr. Matthew Watson
Five total abstracts presented at ASPN 2024 Five total abstracts presented at ASPN 2024
Continued here:
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
Chromocell to Participate in the Virtual Investor Lunch Break Series
By Dr. Matthew Watson
Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET
More here:
Chromocell to Participate in the Virtual Investor Lunch Break Series
Kane Biotech Announces Issuance of Restricted Share Units
By Dr. Matthew Watson
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the third amended and restated performance and restricted share unit plan of the Company dated May 22, 2024 (the “PRSU Plan”). Each RSU is exercisable into one common share of the Company (a “Share”). The RSUs will vest at different times, but none will vest earlier than 12 months from the date of grant.
The rest is here:
Kane Biotech Announces Issuance of Restricted Share Units
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
By Dr. Matthew Watson
Live video webcast on Wednesday, July 17th at 12:00 PM ET
Read the rest here:
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
By Dr. Matthew Watson
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month.
Go here to read the rest:
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
By Dr. Matthew Watson
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Read this article:
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
Abivax Provides Operational and Key Program Update
By Dr. Matthew Watson
Abivax Provides Operational and Key Program Update
See the original post here:
Abivax Provides Operational and Key Program Update
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
By Dr. Matthew Watson
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
See the original post here:
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024
By Dr. Matthew Watson
MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time.
Read more here:
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024
Glass House Brands Welcomes Hector De La Torre Back to The Board of Directors
By Dr. Matthew Watson
LONG BEACH, Calif. and TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., announced today the reappointment of Hector De La Torre to the Company's Board of Directors. Mr. De La Torre previously served as an original member of the Board until 2023, when he stepped down due to time restraints connected to other commitments.
More:
Glass House Brands Welcomes Hector De La Torre Back to The Board of Directors
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
By Dr. Matthew Watson
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 -
Tilray Brands, Inc. to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on July 29, 2024
By Dr. Matthew Watson
NEW YORK and LEAMINGTON, Ontario, July 15, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, today announced that the Company will release financial results for its fourth quarter and full fiscal year ended May 31, 2024 on July 29, 2024 at market close.
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
By Dr. Matthew Watson
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China
Follow this link:
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
By Dr. Matthew Watson
Attachment
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
By Dr. Matthew Watson
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th.
See original here:
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024